The global veterinary auto-immune therapeutics market is projected to grow steadily, increasing from USD 42,815.7 million in 2023 to USD 71,720.6 million by 2033, registering a compound annual growth rate (CAGR) of 5.3% during the forecast period. This growth is attributed to rising awareness of animal health, increasing pet ownership, and advancements in veterinary medicine.
Auto-immune diseases in animals, such as immune-mediated hemolytic anemia (IMHA) and rheumatoid arthritis, have led to the development of specialized therapeutics tailored for veterinary applications. With pet owners seeking improved treatments and the livestock industry demanding robust solutions for maintaining herd health, the market is experiencing significant demand.
Additionally, ongoing innovations in biologics, immunomodulators, and targeted therapies are bolstering the market. However, challenges such as high costs of advanced treatments and limited awareness in emerging regions could impede growth.
Full Report Revealed – https://www.futuremarketinsights.com/reports/animal-auto-immune-disease-therapeutics-market
Key Takeaways:
- The veterinary auto-immune therapeutics market is projected to grow at a 5.3% CAGR, reaching $71.7 billion by 2033.
- Increasing pet ownership and the need for advanced treatments drive demand.
- Innovations in biologics and immunomodulators enhance the efficacy of veterinary therapeutics.
- Cost constraints and awareness gaps in developing regions may present growth challenges.
Market Drivers
- Increasing Incidence of Autoimmune Diseases: The rising prevalence of autoimmune conditions in animals is driving demand for effective therapeutic options.
- Advancements in Treatment Options: The development of new drugs and therapies, including biologics and immunotherapies, is enhancing treatment efficacy for various autoimmune disorders in veterinary medicine.
- Growing Pet Ownership: An increase in pet ownership and the humanization of pets are leading to higher expenditures on veterinary care, including treatments for autoimmune diseases.
- Heightened Awareness of Animal Health: Increased awareness among pet owners regarding the health and well-being of their animals is driving demand for advanced therapeutic solutions.
- Research and Development Investments: Significant investments in R&D are fostering innovations in veterinary auto-immune therapeutics, leading to improved treatment options.
- Zoonotic Disease Concerns: The growing concern over zoonotic diseases (diseases that can be transmitted from animals to humans) is prompting more focus on effective treatments for autoimmune conditions in animals.
Regional Insights
- North America is expected to dominate the veterinary auto-immune therapeutics market due to a large population of companion animals and advanced veterinary healthcare infrastructure.
- The Asia-Pacific region is anticipated to witness significant growth driven by increasing pet ownership and rising healthcare expenditures on animal health.
What are the emerging trends in veterinary auto-immune therapeutics
The veterinary auto-immune therapeutics market is witnessing several emerging trends that are shaping its growth and development. Here are the key trends:
1. Advancements in Monoclonal Antibodies (mAbs)
The approval and use of monoclonal antibodies for treating various autoimmune conditions in pets are gaining traction. Recent approvals, such as Zoetis’s Solensia and Librela for pain management in cats and dogs, respectively, highlight the potential of mAbs to provide targeted therapies for conditions like allergies and osteoarthritis. This trend is expected to expand further into other disease categories such as renal diseases and cancer, with ongoing research focusing on developing more mAb therapies tailored for veterinary applications
2. Increased Focus on Gene Therapy
Innovations in gene therapy, particularly for treating genetic disorders and autoimmune diseases in animals, are emerging. Companies like LEAH Labs are exploring gene editing methods to develop effective treatments for conditions such as canine B cell lymphoma. This approach represents a significant shift towards more personalized and precise therapeutic options in veterinary medicine
3. Use of Cellular Therapies
There is a growing interest in cellular therapies, including stem cell treatments and CAR-T cell therapies, which are being developed to address autoimmune diseases in animals. These therapies aim to modify or enhance the immune response, providing new avenues for treatment that could potentially improve outcomes for affected animals
4. Enhanced Diagnostic Techniques
Advancements in diagnostic technologies are improving the detection and diagnosis of autoimmune diseases in pets. Early detection allows for timely intervention, which is crucial for managing these conditions effectively. Enhanced diagnostics are also leading to better monitoring of treatment efficacy
5. Rising Awareness of Zoonotic Diseases
The increasing concern over zoonotic diseases—those that can be transmitted from animals to humans—is driving awareness and research into autoimmune conditions in companion animals. This trend is prompting pet owners and veterinarians to seek more effective therapeutic options to manage these diseases
What is the Competition Landscape in the Veterinary Auto-Immune Therapeutics Market?
Market players are employing various organic and inorganic strategies including mergers & acquisitions, partnerships, collaborations, etc. in order to consolidate their position in the veterinary auto-immune therapeutics market.
A few of the recent developments in the veterinary auto-immune therapeutics market are:
- A company called Luvig Pharmaceuticals, Inc. announced its establishment in May 2022 with the goal of creating innovative pharmaceuticals that cure autoimmune illnesses without impairing healthy immune function and promote systems of immunological homeostasis. The business has completed a US$ 47 million Series A funding to support this goal, which was headed by Novo Holdings A/S and Platanus and included Bristol-Myers Squibb, Digitalis Ventures, and Mission BioCapital.
- Leading provider of life science solutions QIAGEN N.V. was purchased by Thermo Fisher Scientific Inc. They operate in 25 nations and offer diagnostic solutions for all geographical areas.
- A unique blood test that displays the risk index of autoimmune illnesses was introduced by Progentec. In 12 weeks, it can evaluate the propensity for systemic lupus erythematosus.
Key Players in the Global Market
- Aratana Therapeutics Inc.
- Pfizer Inc.
- Vet-Stem Inc.
- Ambrx Inc.
- Taconic Biosciences Inc.
- JBS United
- Virbac
- Eli Lily and Company
- Jaguar Animal Health Inc.
Veterinary Auto-immune Therapeutics Market Segmentation
By Therapy Type:
- Corticosteroids
- Azathioprine
- Cyclosporine
- Mycophenolate
- Leflunomide
- Cyclophosphamide
- Levothyroxine
- Folic Acid
- Hydrochloroquine
- Chloroquine
By Disease Indication:
- Hypothyroidism
- Pemphigus Disease
- Canine Lupus
- Auto-immune Hemolytic Anemia
- Bollous Pemphigoid
- Discoid Lupus Erythematosus (DLE)
- Immune-related Arthritis
- Others
By Animal Type:
- Companion Animal
- Dogs
- Cats
- Horse
- Swine
- Cattle
- Live Stock Animal
- Poultry
- Fish
- Sheep
By Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
